Glofitamab before stem cell transplant for relapsed DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
- You have tried at least two different cancer treatments, but the lymphoma has come back or hasn't fully responded.
- You are between 18 and 70 years old.
- You have not had a stem cell transplant before.
- You are generally well enough to do most daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial combines glofitamab and selinexor to treat diffuse large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if this two-drug combination works better than standard options.
This study looks at how well the drug glofitamab works and how safe it is for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or hasn't gotten better after treatment. It's for adults in China who are either about to start glofitamab or have started it within the past 6 months.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This trial tests the drug glofitamab given before or after a stem cell transplant for patients whose B-cell lymphoma has returned or not improved. It aims to see if glofitamab can help make the transplant more effective or prevent the cancer from coming back.
This trial tests combining radiation therapy with a drug called glofitamab (a type of immunotherapy) for patients whose diffuse large B-cell lymphoma (DLBCL) has returned or stopped responding to previous treatments. The goal is to see if adding radiation to this newer drug helps control the cancer better.
Hear when a new Diffuse Large B-cell Lymphoma(DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.